SCHEMBL21451005

SCHEMBL21451005

CC(C)(C)OC(=O)N1CCN(c2nc3ccccc3c3c(=O)c4cc(F)ccc4sc23)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 2/20 0.49
TOP1 P11387 1/20 0.46
TOP2A P11388 1/20 0.46
OPRM1 P35372 1/20 0.42
OPRD1 P41143 1/20 0.42
OGFRL1 Q5TC84 1/20 0.42
KIT P10721 2/20 0.42
GRIA1 P42261 1/20 0.41
TP53 P04637 1/20 0.41
DTYMK P23919 1/20 0.40
CKS1B P61024 1/20 0.40
SKP1 P63208 1/20 0.40
SKP2 Q13309 1/20 0.40
HRH4 Q9H3N8 1/20 0.40
TLR9 Q9NR96 4/20 0.40
TLR7 Q9NYK1 2/20 0.40
IDO1 P14902 1/20 0.40
TDO2 P48775 1/20 0.40
IDO2 Q6ZQW0 1/20 0.40
GPR119 Q8TDV5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21451064 0.94 HRH4 (0.43) GBA1TOP1TOP2AOPRM1OPRD1
SCHEMBL21451020 0.84 HRH4 (0.56) TOP1TOP2AHRH4
SCHEMBL21875221 0.83 GBA1 (0.51) GBA1TOP1TOP2AOPRM1OPRD1
SCHEMBL21450998 0.82 TOP1 (0.56) TOP1TOP2AHRH4TLR7
SCHEMBL21450999 0.82 TOP1 (0.55) TOP1TOP2AHRH4TLR7
SCHEMBL21451000 0.81 MAPT (0.51) GBA1TOP1TOP2AHRH4
SCHEMBL21451011 0.80 TOP1 (0.53) TOP1TOP2AHRH4
SCHEMBL21451019 0.80 TOP1 (0.69) TOP1TOP2AOPRM1HRH4
SCHEMBL21450991 0.79 TOP1 (0.52) TOP1TOP2AHRH4ACHE
SCHEMBL21451007 0.78 HRH4 (0.43) TOP1TOP2ATP53HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332476-B2 Fms-like tyrosine kinase inhibitors 3SM BIOTRON INC. (TW) 2022-05-17 US disclosed
US-11332476-B2 Fms-like tyrosine kinase inhibitors 3SM BIOTRON INC. (TW) 2022-05-17 US disclosed
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS Sagabio Co., Ltd. (TW) 2020-04-30 US disclosed
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS Sagabio Co., Ltd. (TW) 2020-04-30 US disclosed
WO-2019191896-A1 FMS-LIKE TYROSINE KINASE INHIBITORS 3SM BIOTRON INC. (CN) 2019-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332476-B2 Fms-like tyrosine kinase inhibitors FLT3, FLT4, FLT1 GBA1 4214/4885TOP1 2980/4885TOP2A 2701/4885
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS FLT3, FLT4, FLT1 GBA1 4214/4885TOP1 2980/4885TOP2A 2701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.